TA Associates Sells $4M Worth of Lumber Liquidators

Stock quotes in this article: LL , CCL , CPY , ...
Click here to read the whole Article (external link)

ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer

RANCHO CORDOVA, Calif., Oct. 19 /PRNewswire-FirstCall/ -- ThermoGenesis (Nasdaq: KOOL - News), a leading supplier of innovative products for processing and storing adult stem cells, said today that Jorge F. Artiles has joined the Company as Vice President, Chief Quality and Regulatory Affairs Officer, effective immediately. Artiles has more than two decades of quality and regulatory affairs experience in the medical device industry, with expertise in quality system development and compliance, project management and process optimization.Most recently, Artiles was Vice President, Quality Assurance and Regulatory Affairs, for Physio Control, a division of Medtronic. Before that, he held a similar position at Cytyc Surgical Products, where he was responsible for quality and regulatory affairs at two manufacturing sites. Artiles has also held quality and regulatory management positions with Teleflex Medical, Abbott Laboratories, Boston Scientific and Baxter Healthcare. He holds a B.S. in Industrial Technology and an M.S. in Quality Assurance and Industrial Technology from San Jose State University."While we have made significant progress with our product quality initiatives over the past year, Jorge brings a level of expertise and experience that will be critical to our growth as we expand our product offerings and develop new market opportunities," said J. Melville Engle, Chief Executive Officer of ThermoGenesis."He has extensive experience in developing and managing quality assurance programs and procedures, implem...
Click here to read the whole Article (external link)

Celling Technologies Announces Initial Success With Res-Q System in Adult Stem Cell Therapy Procedures

RANCHO CORDOVA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL - News), a leading supplier of innovative products for processing and storing adult stem cells, said today its Res-Q(TM) 60 BMC ("Res-Q") System has demonstrated positive outcomes in its initial applications, according to its orthopedic distribution partner Celling Technologies, a subsidiary of SpineSmith, LLC. In a press release issued by Celling Technologies yesterday, Dr. Mustasim Rumi of Round Rock Orthopedics said, "The Res-Q System was able to yield a high concentration of mononuclear cells, which I believe is one of the key ingredients to bone growth. This technology and Celling's service team provided me with the confidence that the cells being processed and the sterility of the procurement is the best in the industry. The market of regenerative therapies will change medicine and I believe that such cutting-edge companies give me the best opportunity to deliver the highest care to my patients," he stated."We are pleased with this early experience with the device as we believe the Res-Q System will help us access the growing regenerative medicine market as it has considerable advantages over competing products and has the potential to help surgeons realize the true value of autologous cellular therapy," said J. Melville Engle, Chief Executive Officer of ThermoGenesis."We believe that point-of-care systems provide an immediate and efficient method for delivering adult stem cell therapy to the patients. Our research has con...
Click here to read the whole Article (external link)

Q1 2010 Thermogenesis Earnings Release - Time Not Supplied

Earnings Announcements for Thursday, November 5CompanySymbolTimeConferenceCall21st Century HoldingTCHC2:00 pm ET3I INFRASTRUCTURE3IN.LBefore Market OpenAbiomed, Inc.ABMDBefore Market OpenListenABOVENET INCABVTAfter Market CloseListenAbraxis BioScience, Inc.ABIIBefore Market OpenListenAccelrys Inc.ACCLAfter Market CloseListenACI Worldwide, Inc.ACIWBefore Market OpenACTIONS SEMICONDUCTOR CO LTDACTSAfter Market CloseActive Biotech ABACTI.STTime Not SuppliedActivision Blizzard, Inc.ATVIAfter Market CloseAdecco SAAHEXF.PK01:00 am ETAinsworth Lumber Company Ltd.ANS.TOAfter Market CloseAir MethodsAIRMAfter Market CloseAker ASAAKERTime Not SuppliedALAMOS GOLD INCAGI.TOBefore Market OpenAlaska Communications Systems GroupALSKAfter Market CloseAlexandria Real Estate...
Click here to read the whole Article (external link)

Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009

RANCHO CORDOVA, Calif., Oct. 30 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL - News), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal first quarter ended September 30, 2009, on Thursday, November 5, 2009. Company's Conference Call and WebcastManagement will host a conference call Thursday, November 5, 2009 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal first quarter financial results.The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, "ThermoGenesis." Mr. J. Melville Engle, Chief Executive Officer and Mr. Matthew Plavan, Executive Vice President, Chief Operating Officer and Chief Financial Officer will host the call to discuss the first quarter results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins.To listen to the audio webcast of the call during or after the event, please visit: http://www.thermogenesis.com/investors-webcasts-and-calls.aspx.ReplayA replay of the conference call will be available two hours after the ...
Click here to read the whole Article (external link)

ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line

RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL - News), a leading supplier of innovative products for processing and storing adult stem cells, today reported results for the first quarter of fiscal 2010. For the quarter ended September 30, 2009, the Company reported revenues of $5.2 million, a 15 percent increase over revenues of $4.5 million in the first quarter a year ago. The Company said the key contributors to the growth in revenues included an increase of approximately $0.5 million, or 40%, in sales of AXP(TM) AutoXpress(TM) (AXP(TM)) disposables over the prior year quarter and new product sales of the MarrowXpress(TM) (MXP(TM)) and Res-Q(TM)60 BMC (Res-Q) Systems.Total disposable revenues in the first quarter of fiscal 2010 increased over 40% to $3.0 million versus $2.1 million in the first quarter of fiscal 2009.The Company reported an 18% reduction in its net loss to $2.2 million, or $0.04 per share, in the first quarter of fiscal 2010, versus a net loss of $2.7 million, or $0.05 per share, in the same period of fiscal 2009. ThermoGenesis ended the first quarter of fiscal 2010 with $13.1 million in cash and short-term investments, compared with $15.6 million at the end of fiscal 2009."We are pleased with the direction of the leading indicators of our quarterly performance, including revenue growth, an improved bottom line and the success of our new products, the MXP and Res-Q Systems, in generating promising new revenues," noted J. Melville Engle, Chief Execu...
Click here to read the whole Article (external link)

THERMOGENESIS CORP Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue5,193  4,023  5,148  6,126  Cost of Revenue3,636  3,617  3,354  3,913  Gross Profit1,557  406  1,794  2,213  Operating ExpensesResearch Development1,594  1,306  1,018  1,298  Selling General and Administrative2,163  2,212  1,917  2,673  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(2,200)(3,112)(1,141)(1,758)Income from Continuing OperationsTotal Other Income/Expenses Net11  28  49  63  Earnings Before Interest And Taxes(2,189)(3,084)(1,092)(1,695)Interest Expense -   -   -   -  Income Before Tax(2,189)(3,084)(1,092)(1,695)Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(2,189)(3,084)(1,092)(1,695)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   -   ...
Click here to read the whole Article (external link)

THERMOGENESIS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi

Show all filings for THERMOGENESIS CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for THERMOGENESIS CORP 5-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibi Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided...
Click here to read the whole Article (external link)